ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
72 announcements with these filters
Lupin Ltd reported annual consolidated revenue of ₹27,958 Crore and recommended a final dividend of ₹18 per share. This performance marks significant growth and shareholder returns.
Lupin Limited received U.S. FDA approval for Glycerol Phenylbutyrate Oral Liquid, a bioequivalent version of Ravicti. The reference product had annual U.S. sales of approximately ₹3201.50 Crore (USD 337 million) in 2025. The drug is indicated for chronic management of urea cycle disorders, strengthening Lupin's specialty generic portfolio in the U.S. market.
Lupin Limited allotted 36,752 fully paid-up equity shares of ₹2 each under its Employee Stock Option plans on May 4, 2026. This allotment increases the company's paid-up share capital to ₹91.44 Crore, consisting of 45,72,15,863 equity shares.
Lupin Limited has launched Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States. This follows approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA). The product is a generic version of Xigduo XR, expanding Lupin's anti-diabetic portfolio in the U.S. market.
Lupin Ltd announced the conclusion of a U.S. FDA inspection at its Somerset, New Jersey facility. The inspection, held from April 13-17, 2026, resulted in a Form-483 with three observations. The company plans to address these observations within the stipulated timeframe and remains committed to CGMP standards.
Lupin Limited incorporated a wholly owned subsidiary, Lupin (Thailand) Limited, on April 17, 2026. The new entity, based in Thailand, will focus on importing, marketing, and distributing pharmaceutical products. It has an initial paid-up capital of 3,000,000 Baht, entirely held by the parent company.
Lupin's US subsidiary, LPI, entered a USD 30 million (₹279 Crore) settlement agreement with Humana Inc. to resolve antitrust litigation in Philadelphia. Lupin denies all allegations of anticompetitive behavior. The settlement amount was already accounted for in prior financial results, ensuring no fresh impact on consolidated earnings.
Lupin Limited has launched Dapagliflozin Tablets (5 mg and 10 mg) in the United States. The product is a bioequivalent generic version of Farxiga®, following approval from the U.S. FDA. This launch expands Lupin's anti-diabetic portfolio in the U.S. market, leveraging its strong position across multiple therapy areas.
Lupin Limited granted 6,495 stock options to employees at an exercise price of ₹ 2.00 per share. These options, granted under the 2011 ESOP plan, vest over a four-year period starting one year from the grant date.
Lupin Limited received U.S. FDA approval for its generic Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, bioequivalent to Xigduo® XR. The company also secured tentative approval for a 2.5 mg/1,000 mg variant. This regulatory milestone enables Lupin to market the anti-diabetic medication in the United States, expanding its metabolic therapy portfolio.
Lupin Ltd has earned the Great Place To Work certification for 2026-27, reflecting its inclusive global workplace culture. The company invested ₹4000.0 Crore in employee benefits during FY25 for its 24,000-strong workforce. This certification marks a significant milestone for the pharma major across its global geographies.
Lupin Limited submitted its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations for the period ended March 31, 2026. The certificate, issued by Registrar MUFG Intime India, confirms that security certificates received for dematerialisation were processed and cancelled within prescribed timelines.